ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.
Metrics to compare | 298380 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship298380PeersSector | |
|---|---|---|---|---|
P/E Ratio | −474.4x | −16.8x | −0.6x | |
PEG Ratio | −10.56 | −0.24 | 0.00 | |
Price/Book | 74.6x | 3.8x | 2.6x | |
Price / LTM Sales | 153.7x | 19.7x | 3.4x | |
Upside (Analyst Target) | −61.3% | 6.3% | 42.5% | |
Fair Value Upside | Unlock | 1.4% | 5.0% | Unlock |